Tuesday - May 6, 2025
LUXEMBOURG / May 08, 2024 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its First Quarter 2024 financial results.
Earnings Release
Wednesday, May 22, 2024
Time: After Market Close
Conference Call
Wednesday, May 22, 2024
Time: 5:00 p.m. ET
Quiet Period
Wednesday, May 8 through Wednesday, May 22, 2024
To participate, please dial
+1 888 596 4144 (Toll-Free)
+1 646 968 2525 (International)
Entry Passcode: 3884034
Webcast: click here
About Auna
Auna is a Latin American healthcare company with operations in Mexico, Peru and Colombia, prioritizing prevention and concentrating on high complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish Speaking Americas. Founded in 1989, Auna has built one of Latin America´s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of December 31, 2023, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,308 beds, and 1.3 million healthcare plans.
For more information visit www.aunainvestors.com
Last Trade: | US$6.97 |
Daily Change: | 0.05 0.72 |
Daily Volume: | 12,105 |
Market Cap: | US$209.100M |
March 10, 2025 March 07, 2025 November 19, 2024 August 21, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load